Regenxbio (NASDAQ:RGNX) will be issuing its quarterly earnings data after the market closes on Wednesday, November 7th. Analysts expect the company to announce earnings of ($0.86) per share for the quarter.
Regenxbio (NASDAQ:RGNX) last issued its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported $0.15 EPS for the quarter, missing the Zacks’ consensus estimate of $1.90 by ($1.75). The company had revenue of $40.03 million during the quarter, compared to the consensus estimate of $100.00 million. Regenxbio had a return on equity of 28.70% and a net margin of 44.44%. On average, analysts expect Regenxbio to post $2 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Shares of NASDAQ:RGNX opened at $70.60 on Monday. The firm has a market capitalization of $2.28 billion, a PE ratio of -28.82, a P/E/G ratio of 14.16 and a beta of -0.49. Regenxbio has a one year low of $23.25 and a one year high of $85.10.
In other news, CFO Vittal Vasista sold 7,500 shares of the company’s stock in a transaction on Wednesday, August 15th. The shares were sold at an average price of $65.43, for a total value of $490,725.00. Following the completion of the sale, the chief financial officer now owns 123,584 shares of the company’s stock, valued at approximately $8,086,101.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Patrick J. Christmas sold 5,000 shares of the company’s stock in a transaction on Monday, August 20th. The shares were sold at an average price of $65.96, for a total transaction of $329,800.00. Following the completion of the sale, the senior vice president now directly owns 22,669 shares of the company’s stock, valued at approximately $1,495,247.24. The disclosure for this sale can be found here. Insiders sold a total of 178,167 shares of company stock valued at $11,214,837 in the last ninety days. 16.90% of the stock is owned by corporate insiders.
RGNX has been the topic of a number of research analyst reports. Morgan Stanley increased their price target on shares of Regenxbio from $37.00 to $92.00 and gave the stock an “overweight” rating in a report on Friday, July 13th. Bank of America lowered shares of Regenxbio from a “buy” rating to a “neutral” rating and increased their price target for the stock from $64.00 to $80.00 in a report on Monday, July 23rd. TheStreet lowered shares of Regenxbio from a “c” rating to a “d+” rating in a report on Friday, August 10th. BidaskClub raised shares of Regenxbio from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Chardan Capital upped their price objective on shares of Regenxbio from $90.00 to $130.00 and gave the company a “buy” rating in a research note on Tuesday, July 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. Regenxbio currently has a consensus rating of “Buy” and an average price target of $77.64.
Regenxbio Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Further Reading: How a Put Option Works
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.